Previous 10 | Next 10 |
Annexon Biosciences (NASDAQ:ANNX): Q3 GAAP EPS of -$0.93 misses by $0.06. Cash and cash equivalents and short-term investments were $271.4 million as of September 30, 2021. Press Release For further details see: Annexon Biosciences EPS misses by $0.06
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, ...
Gainers: ABVC BioPharma (NASDAQ:ABVC) +250%, ANI Pharmaceuticals (NASDAQ:ANIP) +51%, Artelo Biosciences (NASDAQ:ARTL) +37%, Nutriband (NTRBW) +34%, Regencell Bioscience (NASDAQ:RGC) +15%. Losers: Centessa Pharmaceuticals (NASDAQ:CNTA) -19%, Mi...
Gainers: NuCana NCNA +24%, GeoVax Labs (NASDAQ:GOVX) +11%, NanoVibronix (NASDAQ:NAOV) +9%, Regencell Bioscience (NASDAQ:RGC) +11%, Petros Pharmaceuticals (NASDAQ:PTPI) +7%. Losers: Editas Medicine EDIT -15%, Annexon (NASDAQ:ANNX) -15%, Happine...
CAMBRIDGE, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophth...
CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophth...
– Recently expanded Autoimmune franchise with advancement of third clinical candidate, ANX009, and strategically expanded into additional autoantibody-driven diseases – – Continued progress in Neurodegeneration franchise with initial Phase 2 data results fro...
Annexon (ANNX) announces the broadening of its autoimmune franchise through advancement of its third clinical-stage product candidate ANX009.The company plans to advance the product into Lupus Nephritis and expansion of the ANX005 clinical program into a second neuromuscular condition, M...
Advancing subcutaneous ANX009 candidate into Phase 1b program in Lupus Nephritis Deepening ANX005 neuromuscular autoimmune pipeline with new Phase 2 program in Multifocal Motor Neuropathy Annexon to host virtual autoimmune R&D event with leading experts on Wednesday, J...
The following slide deck was published by Annexon, Inc. in conjunction with this event. For further details see: Annexon (ANNX) Presents At Raymond James Human Health Innovation Conference - Slideshow
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 17:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Protective Effects of ANX007 on Visual Acuity and Vision Related Anatomical Measures in the Central Macula Will be Presented as a Late-Breaking Oral Presentation Topline Phase 2 ARCHER Trial Results Will be Discussed as an Oral Presentation BRISBANE, Calif., July 11, 2024 (GLOBE N...
ANX005-Treated Patients Demonstrated Faster and More Complete Recovery from Week 1 through Week 26 on Primary and Multiple Pre-Specified Endpoints Two and a Half Times More ANX005-Treated Patients Returned to a Normal / Pre-Disease State of Health Over Placebo on GBS-DS by Week 26, Increa...